| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04420713d8ca0e51f499cd44298a4692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c09ad2a3c16c669bbfff24e9198266b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a2d43999ee3aadb1d977c2288f68e35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_502daabbcb2f6150b773f015da407d6e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate |
2006-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d0f6ab7751b519a0e66516e286a1348
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea91c461dadbd99152732c88a2803d0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c770fce0b0b821f9903bb173ddfae625 |
| publicationDate |
2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007054514-A3 |
| titleOfInvention |
Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
| abstract |
The invention relates to use of a phosphodiesterase type III (PDE . Ill) inhibitor or Ca 2+- sensitizing agent or a pharmaceutically acceptable derivative thereof for preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size of a patient, suffering from asymptomatic (occult) heart failure. |
| priorityDate |
2005-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |